Raymond Cohen: So, I guess the hot flash is that the trial date has been pushed, so we’re now – it was originally scheduled for mid-April, it’s now scheduled for mid-August, and I really don’t think there’s much more to say that we haven’t said before unless, Dan, you want to add?
Dan Dearen: No, I mean I think the only thing I would add is a standard thing we always say, which is I mean going all the way back to 2019 when these claims were filed against us, which we’ve always said that we don’t believe were infringing on any patent claims. We take this very seriously, but at some point this will be tried and then we’ll report out on it, so, as Ray said, it’s been pushed now to August and we still maintain our position, we haven’t infringed on anything.
David Rescott: Okay, great, thank you.
Operator: Thank you. Our next question comes from the line of Adam Maeder with Piper Sandler. Your line is now open.
Adam Maeder: Hi, Ray. Hi, Dan. Good afternoon and thanks for taking the questions and congrats on a nice Q4 and 2022 year. Maybe Dan for you wanted to just kind of flush out some of the P&L assumptions to the extent you’re willing to share just around kind of OpEx spend, how to think about that and cadence of spending as well as the level of DTC spend in 2023? Thanks.
Dan Dearen: Okay, So, we’re just – Adam, good to hear from you. Just we’re working off the same baseline, adjusted operating expenses in ’22 were $240 million and so that includes stock-based compensation, as well as depreciation and amortization, what it would exclude are the non-cash charges related to the contingent consideration or milestone payment that for the acquisition of Bulkamid. Keep in mind, we have a milestone payment of $35 million when we sell a certain amount of Bulkamid in the trailing 12-month period. Now looking at operating expenses, with that same platform, in 2023, we expect the total OpEx to be $280 million. It’s a mid-teens increase above ’22 and when you back that up against the 25% year-over-year increase in revenue for SNM and Bulkamid it just reiterates the operating leverage that we expect to see.
Adam Maeder: Really helpful, Dan, and thank you for the color there. And for the follow-up, I wanted to ask about it, one of the staff, I hope I heard it correctly that you guys provided in the prepared remarks, but I think you said you have nearly 1,000 physician implanters doing SNM in United States, I was wondering if you’re able to kind of give a little bit more detail there and also remind us kind of how you kind of view market concentration and how fragmented the volumes are and then I guess the other part of the question is how do you think about that number kind of where can it go over time? Thanks so much for taking the questions.
Raymond Cohen: Yeah, thanks, Adam. So I’m trying to parse the question a couple of pieces here. So, if you take – the math is not that hard to come to, if you take the sacral neuromodulation revenue that we did in 2022 and divide it by the average selling price of, call it, $15,500, divided by the number of customers, then there it is, right, it comes out to about 14 SNM implants per customer and these are not accounts, these are – this is a physician count, right, so you could have four physicians in a given group urology practice, which may or may not be owned by the hospital, right, so that’s kind of how we look at it, so those are the averages. We’ve kind of avoided this as you know, Adam, we’ve avoided this in the early days, just because it’s all over the board when you are first starting and you get some implanters that might be doing 50 a year, that’s a great customer, right, and then some that may – they may just getting reinvigorated and they may only do six, so that’s where you come about that average.
